Naloxone price increases may threaten public safety

A price increase for a popular form of the medication, naloxone, threatens the ability of non-profit programs and organizations, including police departments around the country, to provide a medical antidote for drug overdoses. » Find out how a dramatic rise in Rx opioid, heroin abuse increased the price

Idiopathic Pulmonary Fibrosis (IPF)

IPF is the progressive formation of thick or scarred tissue in the lungs, resulting in loss of oxygen. While there is currently no known cause, continued research seeks to find an answer, alongside improved diagnosis and treatment options. Learn More

First FDA-licensed test approved for confirming human T-cell lymphotropic virus I/II

MP Diagnostics HTLV Blot 2.4 (MP Biomedicals) has been approved by FDA as the first FDA-licensed supplemental test for human T-cell lymphotropic virus-I/II (HTLV-I/II). It is a qualitative enzyme immunoassay test, which is to be used to confirm the presence of HTLV antibodies as well as to differentiate between HTLV-I and HTLV-II infection. » Details on this new licensed test

Continuing Education

MTM essentials for smoking cessation

This month's CE activity is part of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to assist pharmacists in providing smoking cessation services for patients interested in quitting smoking..

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 14DT13-KCE28.

Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

ASH: Data released on largest clinical trial of myelofibrosis patients treated with ruxolitinib

Data from the largest clinical trial of myelofibrosis patients treated with ruxolitinib (Jakavi, Novartis) support its safety profile and efficacy benefit, as measured in primary and secondary end points, according to a study presented at the 56th Annual Meeting of the American Society of Hematology (ASH) in San Francisco.
» Details

• ED: Multiple treatment options

• Newly approved blood test predicts organ transplant rejection in children

RESOURCES

Latest Clinical News